Compare Natera Inc. Common Stock (NTRA) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.16 (market cap $298.34M). The key difference: Natera Inc. Common Stock is far larger — about 191.2× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| NTRA | YMAG | |
|---|---|---|
Market Cap | $57.03B | $298.34M |
Volume | 1,131,157 | 1,081,943 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $15.68 |
52-Week Low | $179.42 | $10.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
YMAG trades at $11.55, up 0.7% today, with a neutral technical signal and bullish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. RSI levels show mixed signals with short-term overbought conditions. Support and resistance levels are tightly clustered around $11-$12, indicating potential for near-term consolidation.
The outlook remains balanced with high distribution yields providing income appeal, though technical indicators suggest limited near-term momentum. Key risks include NAV stability during earnings periods and dependency on underlying option strategies. Analyst coverage is limited, requiring careful monitoring of component fund performance and distribution sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
